|
| 阿仑膦酸钠对绝经后骨质疏松症患者骨代谢指标的影响 |
| Effect of alendronate on bone turnover biomarkers in postmenopausal osteoporosis |
| |
| DOI： |
| 中文关键词: 双膦酸盐 绝经后骨质疏松症 骨转换指标 骨特异性碱性磷酸酶(BAP) 抗酒石酸酸性磷酸酶(TRAP-5b) |
| 英文关键词:Bisphosphonate Postmenopausal osteoporosis Bone turnover biomarkers Bone specific alkaline phosphatase (BAP) Tartaiic^'esistant acid phosphatase (TRAP-5b) |
| 基金项目: |
|
| 摘要点击次数: 1257 |
| 全文下载次数: 1085 |
| 中文摘要: |
| 目的观察抗骨吸收药物双膦酸盐对绝经后骨质疏松症患者骨代谢状态的影响。方法本研究为回顾性研究，共收集 在我院骨质疏松门诊数据库中临床资料完整的女性绝经后骨质疏松症患者152例，其中阿仑膦酸钠治疗组93例(A组），每周 给予阿仑膦酸钠70 mg，一次口服;未服用阿仑膦酸钠对照组59例(B组）。分别观察治疗前和治疗后3、6、12个月骨转换生化 指标:骨特异性碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶(TRAP-5b)及25羟维生素D(25( OH) VD)的变化。结果A组患者 经阿仑膦酸钠治疗3个月后BAP和TRAP-5b水平分别较治疗前下降30. 60%和32. 95%( P <0. 001)治疗6个月时完全降至 女性绝经前水平，并一直维持在此水平至治疗后12个月。B组患者治疗前后BAP和TRAP-5b水平差异无统计学意义。结论 绝经后骨质疏松症患者骨代谢处于高转换状态，其BAP及TRAP-5b水平较绝经前明显升高;经阿仑膦酸钠治疗3个月后高 转换状态可以明显改善，骨转换指标BAP和TRAP-5b水平回落到绝经前水平。 |
| 英文摘要: |
| Objective To observe the effect of bisphosphonates (Fosamax) on bone turnover biomarkers in postmenopausal osteoporosis women. Methods A retrospective study was performed. A total of 152 postmenopausal osteoporosis women with complete clinical data，who were selected from the out-patients osteoporosis clinical database of our hospital，were divided into 2 groups ： the alendronate treatment group (Group A，n =93) and the control group (Group B，n =59). Patients in Group A took an oral medication of 70mg alendronate tablets (Fosamax) once a week. And patients in group B were treated without the medication of alendronate. The bone turnover biomarkers，including the changes of bone specific alkaline phosphatase (BAP)，tartaric-resistant acid phosphatase (TRAP-5 b)，and 25 -hydroxy vitamin D (25( OH) VD)，were observed before the treatment and at the 3rd，the 6th，and 12th month after the treatment. Results After 3-^nonth treatment，the serum levels of BAP and TRAP-5 b in Group A decreased by 30. 60% and 32. 95%， respectively， compared with that before the treatment (P < 0. 001)， And after 6^nonth treatment，they totally fell back to the level similar to that in premenopausal women，and remained at this level until 12 months after the treatment. On the contrary，no significant difference of the serum levels of BAP and TRAP-5 b before and after the treatment in Group B was observed. Conclusion The bone metabolism in postmenopausal osteoporosis patients is at a high turnover status， and the serum levels of BAP and TRAP-5 b increased significantly compared to that in premenopausal women. After 3^nonth treatment with alendronate，the high turnover status can be significantly improved，and the levels of serum BAP and TRAP-5 b can fall back to the premenopausal levels. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |